명의 월스트리트 애널리스트에 따르면, Prophase Labs Inc의 매출 추정치는 $에서 $까지입니다.
Prophase Labs Inc의 수익 품질 점수는 얼마인가요?
Prophase Labs Inc의 수익 품질 점수는 B+/53.375137입니다. 이 점수는 수익성, 성장, 현금 창출 및 자본 배분, 레버리지의 네 가지 차원을 기반으로 합니다.
Prophase Labs Inc는 언제 수익을 보고하나요?
Prophase Labs Inc의 다음 수익 보고서는 2026-07-14에 발표될 예정입니다.
Prophase Labs Inc의 예상 수익은 얼마인가요?
월스트리트 애널리스트에 따르면 Prophase Labs Inc의 예상 수익은 $9.86M입니다.
Prophase Labs Inc은 수익 기대치를 충족했나요?
Prophase Labs Inc의 최근 수익은 $로, 기대치를 .
주요 통계
이전 종가
$0.1288
시가
$0.1225
일일 범위
$0.12 - $0.1225
52주 범위
$0.07 - $6.7
거래량
11.4K
평균 거래량
841.6K
배당수익률
0.00%
EPS(TTM)
-0.16
시가총액
$788.4K
PRPH란 무엇인가요?
ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. The company is headquartered in New York City, New York and currently employs 96 full-time employees. The firm is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. The company develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The firm also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.